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Abstract 
Asthma is a chronic inflammatory disease of the airways. It is characterised 
by allergic airway inflammation, remodelling and hyperresponsiveness (AHR). 
Asthma patients, in particular those with chronic or severe asthma, have 
airway remodelling that is associated with the accumulation of extracellular 
matrix (ECM) proteins, such as collagens. Fibulin-1 (Fbln1) is an important 
ECM protein that stabilises collagen and other ECM proteins. Fbln1c, one of 
the four Fbln1 variants, which predominates in both humans and mice, is 
increased in the serum and airways fluids in asthma but its function is unclear. 
We show that Fbln1c protein was increased in the lungs of mice with house 
duct mite (HDM)-induced chronic allergic airway disease (AAD). Genetic 
deletion and therapeutic inhibition of Fbln1c in mice with chronic AAD reduced 
airway collagen deposition, and protected against AHR. Fbln1c deficient (–/–) 
mice had reduced mucin MUC5AC, but not MUC5B protein levels in the 
airways compared to wild-type (WT) mice. Fbln1c interacted with fibronectin 
and periostin that was linked to collagen deposition around the small airways. 
Fbln1c–/– mice with AAD also had reduced α-smooth muscle actin positive 
cells around the airways and reduced airway contractility compared to WT 
mice. These mice also had less airway inflammatory cells, as well as reduced 
levels of IL-5, IL-13, IL-33, TNF and CXCL1 levels in the lungs, and IL-5, IL-
33, and TNF protein in lung-draining lymph nodes after HDM challenge. 
Therapeutic targeting of Fbln1c reduced the numbers of GATA3+ Th2 cells in 
lymph nodes and lungs after chronic HDM challenge. Treatment also reduced 
the secretion of IL-5 and IL-13 protein from co-cultured dendritic cells and T 
cells re-stimulated with HDM. Human epithelial cells cultured with Fbln1c 
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peptide produced more CXCL1 mRNA than medium-treated controls Our data 




Asthma is a chronic inflammatory respiratory disease predominantly of the 
airways. It is characterised by airway inflammation and remodelling that leads 
to airway hyperresponsiveness (AHR) and reversible airflow obstruction [1,2]. 
Clinical symptoms include shortness of breath, wheeze, chest tightness and 
dry cough [3]. There are more than 300 million people suffering from asthma 
worldwide [4]. Asthma exacerbations are a major problem causing increased 
symptoms and hospitalisations and are triggered by multiple allergic and 
exogenous stimuli, such as respiratory infections, house dust mites (HDM), 
pollen, and occupational chemicals [5,6]. The symptoms of disease can be 
controlled in mild to moderate allergic asthmatics using combination therapies 
with inhaled corticosteroids and long acting- agonists, while new biologics 
such as omalizumab (anti-IgE antibody), dupilumab (anti-IL-4R antibody) 
and mepolizumab (anti-IL-5) are also showing promise [1,2]. However, these 
medications only treat the symptoms, while the underlying disease features, in 
particular chronic airway remodelling, are not altered.  
Airway remodelling is an important feature of chronic asthma, which 
includes excessive extracellular matrix (ECM) production and collagen 
deposition leading to airway fibrosis, increased airway smooth muscle (ASM) 
cell mass, mucus hypersecretion and elevated numbers of 
fibroblasts/myofibroblasts [7-9]. Aberrant deposition of ECM proteins is a 
hallmark characteristic of chronic asthma that causes airway stiffening and 
narrowing, and differences in ECM protein expression may represent a 
specific asthma endotype(s) [10]. There are significant increases in type I and 
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III collagen gene expression and protein content in the airways in chronic 
asthma [11,12]. In contrast, type IV collagen deposition is decreased around 
the airways [13]. Other ECM components, including fibronectin (Fn), tenacin-c 
(Tnc) and periostin (Postn), have also been shown to occur at aberrant levels 
in the airways of asthma patients [14-16].  
Fibulin-1 (Fbln1) is a secreted glycoprotein found in the ECM in asthma 
[17]. It facilitates the stabilisation of other ECM proteins, including Fn, Postn 
and Tnc in the lung [18,19]. There are four variants of Fbln1 (Fbln1a, b, c and 
d) in humans, with each one expressing a different C-terminal sequence. 
Fbln1c and d are the predominant variants in adult humans and mice [20]. We 
have shown that the levels of total Fbln1 protein are increased in the serum 
and bronchoalveolar lavage fluid (BALF) of asthma patients compared to non-
asthmatic subjects [21]. Our in vitro studies have shown that stimulation of 
ASM cells from asthmatic patients with TGF-β increases the levels of 
secreted Fbln1 protein [21]. However, the protein levels specifically of Fbln1c 
in asthma patients are unknown. We also showed that antisense 
oligonucleotide silencing of Flbn1c reduces ASM cell proliferation [21], and 
that Fbln1c deficient (–/–) mice have less collagen around the small airways in 
a mouse model of chronic asthma [22]. However, the in vivo function of Fbln1 
in asthma, and in particular its role in airway remodelling and inflammation 
has not been assessed. 
In this study, we demonstrate that Fbln1c is essential for the 
development and progression of airway remodelling in chronic HDM-induced 
experimental asthma (allergic airway disease [AAD]). Deletion of Fbln1c in 
mice prevents the development of airway fibrosis and collagen deposition, as 
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well as inflammation. This suggests that Fbln1c may be a novel therapeutic 
target in the treatment of airway diseases such as asthma by suppressing 
chronic disease characteristics, such as airway remodelling and inflammation.  
 
Materials and Methods 
Additional details are provided in supplementary materials, Supplementary 
materials and methods. 
 
All mouse experiments were approved by the Animal Ethics Committee of The 
University of Newcastle. 
 
Mice and HDM-induced experimental chronic asthma 
Six to eight-week-old female WT or Fbln1c–/– C57BL/6J mice were housed in 
specific pathogen free conditions. Fbln1c–/– mice were generated as described 
previously [22]. Experimental chronic asthma was induced by intranasal 
administration of HDM extract (Geer Laboratories, Lenoir, NC, USA) at 25 μg 
in 30 μl sterile saline for five consecutive days per week for five weeks to 
induce the hallmark features of chronic asthma including airway remodelling 
as previously described [22,23] (Figure 1A). Control mice received sterile 
saline only. Some mice were treated intranasally with 40 g Fbln1c siRNA or 
scrambled siRNA (Dharmacon, Lafayette, CO, USA) [22]  or nuclease free 
water (vehicle) from day 21 to day 35 after the initiation of airway remodelling.  
 
Airway remodelling and AHR 
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Sections of formalin-fixed paraffin embedded mouse lung were deparaffinised 
and collagen was stained using a Sirius Red and Fast Green stain (Sigma-
Aldrich, Castle Hill, NSW, Australia). Airway remodelling in terms of collagen 
deposition around the small airways was analysed using ImageJ (version 
1.47, Media Cybernetics, Rockville, MD, USA) [22,24]. AHR was measured as 
described previously [25-27].  
 
Protein extraction, immunoblotting, hydroxyproline and soluble 
collagen assays 
Lung tissues were homogenised, proteins were detected using antibodies, 
hydroxyproline content and soluble collagen in whole mouse lungs were 
assessed as described previously [22,28-33] and in supplementary material, 
Supplementary materials and methods. 
 
Mucus secreting cells  
Mouse lung sections were stained with Periodic acid-Schiff (PAS) and the 
number of mucus secreting cells around the airways were enumerated 
[29,34].  
 
Immunostaining and immunofluorescence assays 
Mouse lung sections were incubated with antibodies described as previously 





Mouse lungs were inflated, sectioned and exposed to increasing 
concentrations of methacholine, and airway contractility was assessed as 
described previously [35,36]. 
 
BALF and ELISA 
BALF was collected, and differential leucocyte counts were determined. 
ELISA were assessed from mice as described previously [22,27,37,38]. 
 
Lymph node and lung assays   
Mouse lung draining lymph nodes and lungs were collected [39]. The cells 
were cultured with or without 5 μg/ml HDM for five days, and the levels of 
secreted IL-5 and IL-13 were measured by ELISA [27,38]. Some cells were 
stained with Th2 cell markers and enumerated by flow cytometry.  
 
Dendritic cell (DC) and T cell cytokine release 
DCs and T cells were isolated, co-cultured and the levels of secreted IL-5 and 
IL-13 were measured by ELISA [39,40]. 
 
In vitro experiments 
Human respiratory epithelial A549 cell line and minimally immortalised 
epithelium-derived basal (BCi-NS1.1) cells were cultured with Fbln1c peptide 
and scrambled peptide as previously described [41]; RNA extraction and 
qPCR were performed as described previously [42,43] in supplementary 




Data are presented as mean ± standard error of the mean (SEM) from 4–8 
mice, in duplicate or triplicate experiments. Statistical analyses are detailed in 
supplementary material, Supplementary materials and methods. 
 
Results 
Airway remodelling and AHR are associated with increased levels 
of Fbln1c in experimental chronic asthma 
Fbln1c mRNA levels were increased in airway smooth muscle cells derived 
from asthma patients [21]. In order to determine the role of Fbln1c in airway 
remodelling in chronic asthma, we employed an experimental model of HDM-
induced chronic asthma as described previously [22,23]. Airway remodelling 
was determined by assessing the levels of collagen deposition around the 
airways. A substantial (two-fold) increase in collagen deposition around the 
small airways was observed in mice exposed to HDM for 21 days, and after 
35 days compared to saline-challenged controls (Figure 1B). The levels of 
type I collagen-1 (Col1a1), the most abundant collagen in the lungs, were 
increased from 28 to 35 days HDM challenge (Figure 1C). These mice also 
developed AHR, characterised by increased airway resistance and decreased 
dynamic compliance in response to increasing concentrations of 
methacholine, compared to controls after 35 days HDM challenge (Figure 
1D). Fbln1 and Fbln1c protein levels were significantly increased in the lung 
tissue from 28 to 35 days of HDM-exposed mice compared to controls, 
assessed using immunoblotting (Figure 1, E,F). Thus, these data show that 
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airway remodelling and AHR are associated with increased levels of Fbln1c in 
the lungs in HDM-induced experimental chronic asthma. 
 
Genetic deletion of Fbln1c protects against airway and lung 
remodelling and AHR in experimental chronic asthma 
In order to assess the role of Fbln1c in airway remodelling and AHR in 
asthma, Fbln1c deficient (–/–) mice were created as we have previously 
described [22], and chronically exposed to HDM. The absence of Fbln1c 
completely inhibited the deposition of collagen around the small airways 
compared to WT mice after chronic HDM challenge (Figure 2A), and our 
previous study showed similar data [22]. Increases in total and soluble 
collagen in lung tissue (Figure 2B), as well as levels of Col1a1 were 
completely inhibited (Figure 2C) in Fbln1c–/– mice. Indeed, levels of collagen 
deposition, total and soluble collagen and Col1a1 in Fbln1c–/– mice exposed 
to HDM were equivalent to baseline levels in saline-challenged control WT 
and Fbln1c–/– mice, which were equivalent to each other.  
Goblet cell hyperplasia/metaplasia and mucus hypersecretion is also a 
chronic feature of asthma. Thus, we assessed the impact of the absence of 
Fbln1c on this feature. Lung sections were stained with PAS, and mucus 
hypersecretion was assessed by quantifying the number of PAS-positive cells 
to a depth of 100 μm beneath the epithelial basement membrane. Chronic 
HDM challenge induced significant increases in the numbers of PAS-positive 
cells in the airways in both WT and Fbln1c–/– mice compared to their controls. 
However, there was no difference between the number of PAS-positive cells 
in the airways of HDM-challenged WT or Fbln1c–/– mice (see supplementary 
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material, Figure S1A,B). We also assessed the levels of mucin MUC5AC and 
MUC5B in the airways using immunofluorescence. Fbln1c–/– mice had 
significantly reduced MUC5AC but not MUC5B protein levels in the airways 
after HDM challenge (supplementary material, Figure S2). 
AHR and wheezing are major disease symptoms of chronic asthma. In 
order to determine whether pathological changes identified in Fbln1c–/– mice 
affected these functional changes, AHR was assessed in terms of increased 
airway resistance and decreased dynamic compliance in response to 
increasing concentrations of methacholine. Increased airway resistance 
(Figure 2D) and decreased dynamic compliance (Figure 2E) were induced in 
response to chronic HDM exposure in WT mice but did not develop in Fbln1c–
/– mice.  
We then assessed whether siRNA to suppress levels of Fbln1c could 
be used therapeutically. Since airway remodelling occurred after 21 days of 
HDM challenge (Figure 1B), Fbln1c-targeted or scrambled siRNA or vehicle 
were administered every two days from day 21 to day 35 of HDM challenge. 
Fbln1c siRNA treatment after the establishment of remodelling reduced the 
levels of collagen deposition around the small airways (Figure 2F) and Col1a1 
protein (Figure 2G) in the lungs. The use of immunoblotting identifies Col1a1 
(125 kDa) from Col1a2 (110 kDa). Treatment also protected against chronic 
HDM-induced AHR (Figure 2H,I). 
These data demonstrate that Fbln1c is necessary for the development 




Fbln1c has varied roles in the accumulation of Fn, Tnc, and Postn 
around the airways and in the lung in experimental chronic asthma 
The increased deposition of ECM proteins underpins airway remodelling, and 
we showed previously that Fbln1 is critical for ECM stabilisation [22]. Thus, 
the role of Fbln1c in the deposition of ECM associated proteins in HDM-
induced chronic asthma was examined. HDM challenge of WT mice resulted 
in substantial (two-fold) increases in the protein levels of Fn, Postn and Tnc 
around the small airways compared to saline-challenged controls (Figure 3A–
C). However, HDM-challenged Fbln1c–/– mice had only a partial increase in 
Fn and were completely protected against increases in Postn. The increase in 
Tnc occurred to the same levels in HDM-exposed Fbln1c–/– and WT mice. 
Next, we assessed the levels of these proteins in the whole lung using 
immunoblots. HDM challenge of WT mice resulted in increased levels of Fn 
and Postn in whole mouse lungs, while Tnc levels were reduced (Figure 3D). 
It should be noted that different isoforms of Tnc can be detected by 
immunoblot but not IHC in which all forms are detected simultaneously. HDM 
challenged Fbln1c–/– mice were completely protected against the increases in 
Fn and Postn that occur in WT mice. The levels of Tnc were reduced in HDM-
challenged WT mice compared to saline-challenged controls. However, there 
was no statistically significant reduction in HDM-challenged Fbln1c–/– mice 
compared to their controls (P=0.165 for isoform 1, P=0.1097 isoform 2). 
These data demonstrate that Fbln1c is necessary for the increased 
levels of Fn and Postn but not Tnc around the airways and in lung tissue in 
HDM-induced experimental chronic asthma. 
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Fbln1c is required for increases in the levels of α-smooth muscle 
actin (α-SMA) positive cells around the airways and contractility of 
the airways in experimental chronic asthma  
Increased numbers of α-SMA positive cells is a major feature of airway 
remodelling in asthma [8,9]. Thus, to further clarify the role of Fbln1c in airway 
remodelling in asthma, we next assessed the number of α-SMA positive cells 
around the airways in Fbln1c–/– and WT mice using immunofluorescence. 
Following chronic HDM challenge of WT mice there was a doubling of α-SMA 
positive cells around the medium (Figure 4A) and small (Figure 4B) airways 
compared to saline-challenged controls. HDM-challenged Fbln1c–/– mice were 
completely protected against these increases in α-SMA positive cells. Indeed, 
the number of α-SMA positive cells in Fbln1c–/– mice challenged with HDM 
was the same as the baseline numbers in saline-challenged control WT and 
Fbln1c–/– mice.  
Increased ASM results in abnormal airway contractility in asthma. 
Thus, we then assessed the role of Fbln1c in airway contraction by measuring 
airway lumen area in response to methacholine in precision cut lung slices 
[35,36]. Chronic HDM challenge of WT mice resulted in a greater reduction in 
airway lumen area compared to saline-challenged controls (Figure 4C). HDM-
challenged Fbln1c–/– mice were protected against this increased contractility, 
which was equivalent to baseline levels in saline-challenged WT and Fbln1c–/– 
mice (Figure 4D). 
These data show that Fbln1c is necessary for the increased levels of α-
SMA positive cells around the airways and increased airway contractility in 
HDM-induced experimental chronic asthma. 
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Fbln1c contributes to pulmonary inflammation in experimental 
chronic asthma 
Chronic airway inflammation is an important feature and driver of 
pathogenesis in asthma. Thus, we next assessed if Fbln1c had any role in 
inflammation in chronic experimental asthma. Total leukocyte numbers as well 
as macrophages, neutrophils, eosinophils and lymphocytes, were significantly 
increased in the BALF of WT mice after chronic HDM challenge (Figure 5A). 
All these cell types were also increased in HDM-challenged Fbln1c–/– mice, 
however the levels of neutrophils, eosinophils and lymphocytes were 
significantly less than in HDM-challenged WT mice. HDM challenge of WT 
mice resulted in significant increases in the levels of the proinflammatory 
cytokines, IL-5, IL-13, IL-33, TNF and the chemokine CXCL1 in the lung 
tissue compared to saline-challenged controls (Figure 5 B–F). However, 
Fbln1c–/– mice were completely protected against HDM-induced increases in 
these factors, with levels no different to those in saline-challenged WT and 
Fbln1c–/– mice, which were equivalent. We also enumerated GATA3+ Th2 
cells in lymph nodes between naive WT and Fbln1c–/– mice by flow cytometry, 
and the found that there were no differences (supplementary material, Figure 
S3). 
Since genetic deletion in Fbln1c–/– mice reduced chronic HDM-induced 
inflammation, the therapeutic effects of Fbln1c-targeted siRNA treatment were 
assessed. Treatment reduced the levels of total leukocytes and neutrophils, 
eosinophils, and lymphocytes (Figure 5G) in BALF, and IL-5, IL-13, IL-33, 
TNF, and CXCL1 proteins (Figure 5 H–L) in the lungs compared to scrambled 
 16 
siRNA treatment or vehicle after chronic HDM challenge. There were also 
fewer GATA3+ Th2 cells in lymph nodes (Figure 5M and supplementary 
material, Figure S3) and lungs (Figure 5N and supplementary material, Figure 
S4) from mice treated with Fbln1c siRNA. 
 
Fbln1c regulates lymph node T-cell cytokine secretion in 
experimental chronic asthma 
In order to further assess the role of Fbln1c in regulating inflammation in 
asthma, the lymph nodes of WT and Fbln1c–/– mice challenged with HDM or 
saline were collected. The secretion of IL-5, IL-13 and TNF were all 
substantially increased from lymph node T-cells from HDM-challenged WT 
mice compared to saline-challenged controls (Figure 6,A-C). T-cells from 
HDM-challenged Fbln1c–/– mice secreted significantly lower levels of IL-5 and 
IL-13, which were no different to baseline levels in saline-challenged WT and 
Fbln1c–/– mice, which were equivalent. T-cells from HDM-challenged Fbln1c–/– 
mice also had lower levels of TNF secretion compared to similarly challenged 
WT mice, although levels were still elevated compared to saline-challenged 
Fbln1c–/– controls. 
We next determined if Fbln1c affected DC and/or Th2 cell activity 
and/or DC-induced Th2 responses by measuring the levels of secreted IL-5 
and IL-13 protein from co-cultured DC and T cells re-stimulated with HDM. 
Fbln1c-targeted siRNA treatment affected both DC and Th2 cells and reduced 
IL-5 (Figure 6D) and IL-13 (Figure 6E) production compared to cells from mice 
treated with scrambled siRNA. This occurred when either Fbln1c siRNA 
treated DCs or T cells were cultured with scrambled siRNA treated T cells or 
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DCs, respectively. The greatest effect was when DCs and T cells were 
isolated from Fbln1c siRNA treated mice and co-cultured. Thus, Fbln1c 
affects DCs and T cells and promotes DC-induced Th2 responses. 
 
Fbln1c induces chemokine mRNA expression from a human 
airway epithelial cell line  
We then undertook studies with human cells to validate some of our findings. 
Fbln1c recombinant protein is not available, and so human Fbln1c and 
scrambled peptides were obtained as described previously [42].  Human 
bronchoepithelial A549 cells and minimally immortalised epithelium-derived 
basal (BCi-NS1.1) cells were cultured on plates coated with Fbln1c, 
scrambled peptides, or were uncoated and contained media only, and RNA 
was extracted after 24 and 48 h. CXCL1 RNA levels were significantly 
increased in cells exposed to Fbln1c peptide compared to culture medium and 
there were non-statistically significant trends towards increases compared to 
scrambled peptide treatment (P<0.06 and P<0.08, respectively, Figure 6F,G). 
 
Discussion  
Increased production and deposition of ECM proteins, resultant airway 
remodelling and hyperresponsiveness, and pulmonary inflammation are key 
pathological features of asthma. Our previous studies have shown that Fbln1 
is increased in BALF and ASM cells from asthma patients compared to 
healthy controls [21]. In this study, we have demonstrated important roles for 
Fbln1c in regulating the chronic features of airway remodelling and 
inflammation in experimental chronic asthma. We found that Fbln1, Fbln1c 
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and collagen proteins are increased in a HDM-induced mouse model of 
experimental chronic asthma. Genetic and therapeutic depletion of Fbln1c 
prevented the increases in chronic HDM-induced collagen around the small 
airways and in the lungs. It also prevented the development of HDM-induced 
AHR. Fbln1c–/– mice had fewer α-SMA positive cells around the airways and 
less airway contractility that likely also contributed to the protection against 
AHR. We also showed that Fbln1c is involved in allergic airway inflammation, 
because depletion of Fbln1c in mice resulted in fewer leukocytes, including 
neutrophils, eosinophils and lymphocytes, which had influxed into the airways 
compared to controls. The levels of proinflammatory cytokines and 
chemokines associated with allergic airway inflammation and the influx of 
neutrophils, eosinophils and Th2 lymphocytes into the lungs were also 
reduced. Fbln1c–/– mice also had reduced levels of IL-5, IL-13 and TNF 
secretion by Th2 cells from lung draining lymph nodes compared to WT mice. 
Depletion of Fbln1c also reduced IL-5 and IL-13 secretion from co-cultured 
DC and T cells after HDM stimulation. In support of the increase in 
inflammatory responses induced by Fbln1c, human epithelial cells exposed to 
a Fbln1c peptide had increased CXCL1 mRNA levels compared to medium-
exposed controls and a trend towards an increase compared to scrambled 
peptide-treated controls. Collectively, these results provide strong evidence 
that Fbln1c plays a key role in airway remodelling, impaired lung function and 
inflammation in experimental chronic asthma. 
We performed a time course study of the development of HDM-induced 
experimental asthma, and measured the levels of collagen deposition around 
the small airways and Col1a1, Fbln1 and Fbln1c proteins in whole lungs. 
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Collagen deposition around the small airways started to occur after 21 days, 
and Col1a1 proteins were increased after 28 days of HDM challenge. Fbln1 
and Fbln1c proteins were also increased after 28 days. However, intranasal 
treatment with Fbln1c-targeted siRNA from day 21 to day 35 reduced collagen 
deposition around the airways and in whole lungs after HDM challenge.  
These data suggest that the role of Fbln1c is to stabilise the formation of 
collagen in lungs after HDM challenge. 
The increased collagen deposition around the small airways of WT 
mice following 35 days of chronic HDM challenge was not observed in 
Fbln1c–/– mice. Fbln1c is important in stabilising ECM protein deposition by 
binding to multiple ECM targets to maintain the structure of the airways and 
lungs [22]. We show that increases in Fn and Postn in the airways and lung 
tissue in experimental chronic asthma are dependent on Fbln1c. This 
suggests that Fbln1c may directly or indirectly bind to multiple ECM targets, 
and organises collagen deposition in chronic asthma. Fbln1 is known to 
directly interact with some ECM proteins, such as Fn [44,45]. Fbln1 binds to 
the heparin II domain in Fn [46], and promotes cell adhesion and has motility-
suppressive effects on Fn-coated substrates [47]. Increased levels of Fn 
proteins have been found around the airways of asthmatic patients [12], and 
this is reflected in our HDM-induced chronic asthma model. A recent study 
demonstrated increased levels of Postn protein in the lungs of asthma 
patients [48]. Furthermore, both Fn and Postn bind to collagen and Fbln1, and 
Postn and Tnc co-localise in skin keratinocytes [19,49,50]. The reduction of 
Fn in whole lungs of Fbln1c–/– mice after HDM challenge likely reflects the 
importance of Fbln1c in stabilising Fn fibres in the ECM matrix. Peribronchial 
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Fn was reduced after HDM challenge in Fbln1c–/– mice, and the amount of Fn 
was reduced in the whole lungs even compared to saline-challenged controls. 
In WT mice we found decreased levels of Tnc protein in whole lungs, but 
increases around airways after HDM challenge. Our previous study also 
demonstrated that the levels of ECM protein were different between airways 
and parenchyma in Fbln1c–/– mice with experimental chronic obstructive 
pulmonary disease (COPD) [22]. The observation of different changes in the 
airways compared to whole lungs suggest that the amount of ECM proteins 
may be produced differently in different regions, such as airways and 
parenchyma. Indeed, fibroblasts/myofibroblasts, ASM cells, and epithelial 
cells are major sources of Fn around airways [21,42], however, fibroblasts 
and alveolar epithelial cells are the primary sources in the parenchyma [51]. 
We previously showed that fibroblasts [42], bronchoepithelial [22] and 
ASM cells [21] all produce Fbln1 in the airways and lungs. In this study, we 
show that Fbln1c regulates the proliferation of ASM cells and 
fibroblasts/myofibroblasts around the airways and lungs. α-SMA is a marker 
for both ASM cells and differentiated fibroblasts (myofibroblasts) [52,53], and 
lower numbers of α-SMA positive cells in Fbln1c–/– mice suggests that the 
numbers of either or both of these cell types were reduced. In this study, we 
also show that Fbln1c regulates ASM contractile activity. As well as 
contraction, ASM cells play important roles in inflammatory responses (e.g., 
by releasing mast cell mediators [54]). The numbers of ASM cells are also 
increased in asthma patients, which possibly results from their increased 
proliferative properties [55,56]. ASM cells also produce and have altered 
responses to ECM proteins in asthma [13], and the proliferation of these cells 
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from asthma patients is reduced after targeting of Fbln1c mRNA [21]. 
Fibroblasts/myofibroblasts are major cellular sources of ECM proteins [57], 
and are increased in the lung tissues of asthmatic children compared to 
healthy controls [58]. Myofibroblasts in particular are a major producer of type 
I and III collagen [59]. Thus, a potential decrease in ASM and/or 
myofibroblasts in our study may be the cause of the reduced collagen 
deposition in Fbln1c–/– mice.  
Mucins play critical roles in mucus secretion and AHR in asthma, and 
previous studies have shown that genetic deletion of MUC5AC prevented 
AAD-induced AHR in mice [60]. We show that Fbln1c–/– mice had reduced 
MUC5AC but not MUC5B proteins in airways compared to WT controls. While 
increased mucus secretion in the lungs occurs in asthma [61], we found that 
the numbers of mucus secreting cells were not different in Fbln1c–/– compared 
to WT mice with chronic experimental asthma. The mechanism behind this 
remains unclear. 
Alterations in individual ECM proteins, such as Fbln1c, Tnc, and Postn, 
change the overall physical properties of the matrix affecting inflammatory cell 
attachment and migration, as well as the ability of the matrix to bind cytokines 
that contribute to inflammation. TNF and IL-33 are profibrotic cytokines, 
involved in airway remodelling [62,63], while the chemokine CXCL1 
contributes to the inflammatory process in asthma [64]. WT mice challenged 
with HDM exhibited significant increases in asthma related cytokines (IL-5, IL-
13, IL-33, and TNF) in their lungs and lung draining lymph nodes. However, 
depletion of Fbln1c in mice protected against increases in these factors in 
chronic experimental asthma. We demonstrate that there were fewer GATA3+ 
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T cells in the lymph nodes and lungs of mice treated with Fbln1c siRNA 
compared to scrambled siRNA. We also showed treatment reduced DC-
induced Th2 responses. This indicates that Fbln1c modifies DC and T cell 
function to promote DC-induced Th2 responses. However, the mechanism 
remains unclear. The decreased inflammation in mice after inhibition of 
Fbln1c may be the result of direct effects on the cellular expression of these 
cytokines and chemokines, or may occur indirectly through reductions in other 
immunomodulatory factors, such as Tnc and Postn. Recent studies 
demonstrate that Tnc–/– and Postn–/– mice have reduced lung inflammation in 
mouse models of asthma [65,66]. Previous studies showed that Fbln1 is 
associated with heparin-binding epidermal growth factor (EGF)-like growth 
factor, indicating that it may induce the EGF receptor signalling pathway to 
promote inflammation [67]. Fbln1 may also bind to integrin 1 suggesting a 
role for the integrin signalling pathway [67]. However, Fbln1c has not yet 
formally been shown to bind to these proteins. To further assess how Fbln1c 
might be controlling inflammation, we attempted an immunoprecipitation to 
identify its binding partners on inflammatory cell surfaces (data not shown). 
However, this failed due to the lack of a suitable Fbln1c antibody.  
CXCL1 is an important chemokine that is released from epithelial cells 
[68], and is involved in regulating inflammatory cells and ASM migration in 
asthma [69,70]. Fbln1c–/– mice had significantly lower levels of CXCL1 protein 
in lung tissue compared to WT mice. Although the exact mechanism remains 
unclear, we show that Fbln1c peptide increased CXCL1 mRNA levels in two 
human epithelial cell lines compared to vehicle but only showed non-
statistically significant trends to increases compared to scrambled peptide-
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treated controls. We interpret these data to indicate that Fbln1c causes 
epithelial cells to secrete chemokines to induce inflammatory responses. 
Collectively, our data suggest that Fbln1c plays a key role in regulating 
airway remodelling and inflammation in chronic asthma. Fbln1c stabilises 
ECM protein deposition, including Fn and Postn, and regulates collagen levels 
around the airways and in lungs that results in airway remodelling and AHR in 
HDM-induced chronic experimental asthma. Fbln1c is required for increases 
in α-SMA positive cells around airways that regulate ASM contraction. Fbln1c 
also regulates airway inflammation associated with the influx of neutrophils, 
eosinophils and lymphocytes, and their related cytokines and chemokines 
with HDM challenge. Fbln1c plays a central role in the process of ECM 
deposition and inflammatory responses, and may be a novel therapeutic 
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Figure 1. Chronic house dust mite (HDM) challenge results in airway 
remodelling and airway hyperresponsiveness (AHR) in association with 
increased Fbln1 and Fbln1c protein levels in the lungs in experimental chronic 
asthma. (A) Mice were chronically exposed to HDM via the airways for 35 
days. Controls received saline. (B) A time course of lung sections was stained 
with Sirius Red and Fast Green (left, scale bar = 50 μm), and collagen area 
around the small airways was quantified and normalised to the perimeter of 
the basement membrane (Pbm). (C) Time course of type I collagen (Col1a1) 
in whole lungs by immunoblot. (D) Airway resistance (left) and dynamic 
compliance (right) were measured in response to increasing concentrations of 
methacholine after 35 days of HDM challenge. Time course of Fbln1 (E) and 
Fbln1c (F) protein levels assessed in whole lung homogenates by immunoblot 
(top), and fold change of densitometry normalised to β-actin (bottom). Results 
are mean ± SEM. n=6-8 mice per group. *P<0.05, **P<0.01, ***P<0.001 
compared to saline-challenged WT controls. 
 
Figure 2. Genetic deletion and therapeutic targeting of Fbln1c in mice 
protects against increased collagen deposition around the small airways and 
in whole lungs, and airway hyperresponsiveness (AHR) in house dust mite 
(HDM)-induced experimental chronic asthma. WT and Fbln1c–/– mice were 
administered HDM to the airways for 35 days. Controls received saline. (A) 
Lung sections were stained with Sirius Red and Fast Green (left, scale bar = 
500 μm; insets show expanded images of indicated regions; scale bar = 50 
μm). Collagen area around small airways was normalised to the perimeter of 
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basement membrane (Pbm, right). (B) Total collagen levels were assessed by 
measuring hydroxyproline (left), and soluble collagen (right) in whole lungs. 
(C) Type I collagen (Col1a1) protein was measured in whole lungs by 
immunoblot (left), and fold-change of type I collagen was normalised to β-
actin and compared to saline-challenged WT controls (right). (D) AHR in 
terms of airway resistance in response to increasing concentrations of 
methacholine challenge (left), and a representative plot of airway resistance at 
the maximal dose (50 mg/ml) of methacholine (right). (E) AHR in terms of 
dynamic compliance in response to increasing concentrations of methacholine 
challenge (left), and a representative plot of dynamic compliance at 50 mg/ml 
of methacholine (right). Mice were administered HDM to the airways for 35 
days to induce experimental asthma and were treated with Fbln1c-targeted or 
scrambled siRNA from day 21 to day 35. (F) Collagen was stained with Sirius 
Red and Fast Green (left, scale bar = 50 μm) and normalised to Pbm (right). 
(G) Col1a1 proteins in whole lungs (left), and fold change of Col1a1 were 
normalised to β-actin (right). Airway resistance (H) and dynamic compliance 
(I) in response to increasing concentrations of methacholine challenge. 
Results are mean ± SEM. n=6–8 mice per group. *P<0.05, **P<0.01, 
****P<0.0001 compared to saline-challenged WT or Fbln1c–/– controls. 
#P<0.05, ##P<0.01, ####P<0.0001 compared to HDM-challenged WT 
controls. $P<0.05, $$P<0.01 compared to HDM-challenged controls with 
scrambled siRNA. 
 
Figure 3. Fbln1c–/– mice are partially or completely protected against 
increased fibronectin (Fn) and periostin (Postn) but increased tenascin-c (Tnc) 
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deposition is unaffected around the small airways or in whole lungs in house 
dust mite (HDM)-induced experimental chronic asthma. (A) Fn, (B) Tnc, and 
(C) Postn deposition around small airways was assessed by 
immunohistochemistry (left) scale bars, 50 μm, and quantification of the areas 
was normalised to the perimeter of the basement membrane (Pbm) (right). (D) 
Protein levels in whole lungs was assessed by immunoblot (left), and fold 
change determined using densitometry normalised to β-actin and compared 
to saline-challenged WT controls (right). Results are mean ± SEM. n=6–8 
mice per group. *P<0.05, **P<0.01 ***P<0.001, ****P<0.0001 compared to 
saline-challenged WT or Fbln1c–/– controls. #P<0.05, ##P<0.01, ###P<0.001, 
####P<0.0001 compared to HDM-challenged WT controls. NS is non-
significant. 
 
Figure 4. Fbln1c–/– mice are protected against increases in α-smooth muscle 
actin (α-SMA) positive cells around medium and small airways, and 
exaggerated airway contractility in house dust mite (HDM)-induced 
experimental chronic asthma. α-SMA (red) and nuclei (blue) staining around 
(A) medium and (B) small airways (left) scale bars = 200 μm, insets show 
expanded image of indicated regions; scale bars = 50 μm. Quantification of α-
SMA area was normalized to the perimeter of the basement membrane (Pbm, 
right). (C) Frame-by-frame analysis showing changes in airway lumen area 
with methacholine (MCh) exposure. (D) Average contraction over the last 
minute of perfusion of each concentration of MCh exposure. Results are 
mean ± SEM. n=6–8 airways from n=5-8 mice per group. *P<0.05 compared 
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to saline-challenged WT or Fbln1c–/– controls. #P<0.05 compared to HDM-
challenged WT controls. 
 
Figure 5. Genetic and therapeutic inhibition of Fbln1c in mice are protected 
against pulmonary inflammation in house dust mite (HDM)-induced 
experimental chronic asthma. WT and Fbln1c–/– mice were administered 
chronic HDM for 35 days. Controls received saline. (A) Differential 
inflammatory cell counts in bronchoalveolar lavage fluid (BALF). (B) IL-5, (C) 
IL-13, (D) IL-33, (E) TNF and (F) CXCL1 protein levels in whole lung 
homogenates measured by ELISA. Mice were administered HDM for 35 days 
to induce experimental asthma and were treated with Fbln1c-targeted or 
scrambled siRNA or vehicle. (G) Differential inflammatory cell counts in BALF. 
(H) IL-5, (I) IL-13, (J) IL-33, (K) TNF and (L) CXCL1 protein levels in whole 
lung homogenates. GATA3+ Th2 cells from lymph nodes (M) and lungs (N) 
were enumerated by flow cytometry. Results are mean ± SEM. n=6–8 mice 
per group. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 compared to saline- 
or dH20-treated WT or Fbln1c–/– controls. #P<0.05, ##P<0.01, ####P<0.0001 
compared to HDM-treated WT controls. $P<0.05, $$P<0.01 compared to 
HDM controls treated with scrambled siRNA. 
 
Figure 6 Genetic and therapeutic depletion of Fbln1c in mice protects against 
increased Th2 cytokine and chemokine production in lung-draining lymph 
nodes in house dust mite (HDM)-induced experimental chronic asthma, as 
well as Fbln1c peptide induced CXCL1 in a human epithelial cell line. Cells 
were isolated from the lymph nodes of WT and Fbln1c–/– mice, cultured with 
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HDM and (A) IL-5, (B) IL-13, and (C) TNF protein levels in supernatants 
measured by ELISA. Mice were sensitised and challenged with HDM for 35 
days to induce experimental asthma and were treated with Fbln1c–targeted or 
scrambled siRNA. Dendritic cells and T cells were isolated from lymph nodes, 
re-stimulated with HDM, and IL-5 (D) and IL-13 protein levels in supernatants 
were measured by ELISA. n=6–8 mice per group. Human epithelial (A549) 
cells (F) and human epithelium-derived basal (BCi-NS1.1) cells (G) were 
cultured with Fbln1c peptide or scrambled peptide or were uncoated and 
contained media only and CXCL1 mRNA levels were measured by Reverse 
Transcription-qPCR. n=6. Results are mean ± SEM. *P<0.05, ****P<0.0001 
compared to saline-challenged WT or Fbln1c–/– controls with HDM re-
stimulation. #P<0.05, ##P<0.01 compared to HDM-challenged WT mice with 
HDM re-stimulation. &P<0.05, &&P<0.01 compared to HDM-challenged mice 
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Airway remodelling  
Isolated mouse lungs were perfused with 0.9% saline at fixed pressure, 
formalin-fixed, paraffin-embedded, sectioned and stained with Sirus Red and 
Fast Green. Photomicrographs were taken using an Aperio AT2 image 
scanner (Leica Biosystems, Wetzlar, Hesse, Germany). Images were 
evaluated and airway remodelling was analysed using ImageJ (version 1.47) 
as described previously [22,24]. Airways were divided into three categories 
according to the perimeter of their basement membrane (Pbm): Pbm ≤1 mm 
(small), Pbm >1 to ≤2 mm (medium) and Pbm > 2mm (large). At least 6 
airways per mouse were blind-selected from 4-6 mice in each experimental 
group. The widths of the perimeter of the basement membrane (Pbm), the 
inner collagen area (Ai), and the outer collagen area (Ao) were measured 
using ImageJ. Collagen area (Wct) was calculated (Wct = Ao-Ai) and 
normalised to the Pbm. 
 
AHR 
Mice were anesthetized with ketamine (40mg/kg, Ceva Animal Health Pty Ltd, 
Glenorie, NSW, Australia) and xylazine (10mg/kg, Troy Laboratories, 
Smithfield, NSW, Australia). Mice were cannulated and attached to a 
ventilator (Buxco Electronics, Sharon, CT, USA). Airway resistance (RL) and 
dynamic compliance (CDyn) were assessed by analysis of pressure and flow 




Lung tissues were homogenised in radioimmunoprecipitation assay (RIPA) 
buffer (Sigma-Aldrich, Castle Hill, NSW, Australia) or PBS supplemented with 
PhosSTOP phosphatase inhibitor and complete protease inhibitor cocktails 
(Roche, Mannheim, Germany) as described previously [28,29,31]. Tissue 
debris was removed by centrifugation (8,000 x g, 10 min, 4 °C), and proteins 
were collected for analysis using immunoblot or ELISA. Protein 
concentrations were determined using a BCA protein assay kit (Pierce 
Biotechnology, Rockford, IL, USA). 
 
Immunoblotting  
Proteins were separated by SDS-PAGE electrophoresis using Mini-
PROTEAN TGX Stain-Free gels (Bio-Rad, USA), and transferred to 
polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). 
Proteins were detected using antibodies, including Fbln1c obtained as 
described previously [17], Fbln1 (ab175204, Abcam, Milton, CB, UK), Col1a1 
(ab21286, Abcam), Fn (F3648, Sigma-Aldrich, St. Louis, MO, USA), Postn 
(ab14041, Abcam), Tnc (sc-20932, Santa Cruz Biotechnology, Santa Cruz, 
CA, USA), and β-actin (ab70165, Abcam). Images of immunoblots were 
captured with a ChemiDoc MP System (Bio-Rad Laboratories, Hercules, CA, 
USA). Blots were cut based on protein molecular weights, so that multiple 
proteins could be detected at the same time. The densitometric values of 
proteins of interest were measured and normalised according to the density of 
internal control proteins, such as β-actin, using ImageJ as described 
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previously [37]. Values are represented as fold-change of the experimental 
groups compared to control groups. 
 
Hydroxyproline assay 
Lung tissues were homogenised in 6N HCl at 130 C for 8 h. Samples were 
incubated with chloramine-T solution (1.4% chloramine-T, 10% N-propanol 
and 80% citrate-acetate buffer [110 mM sodium acetate trihydrate, 20 mM 
citric acid, 75 mM sodium hydroxide, pH 6.5]) at room temperature for 20 min, 
and incubated with Ehrlich’s solution at 65 C for 18 min. Absorbance was 
measured at 558 nm. The concentrations of hydroxyproline (Sigma-Aldrich) 
were determined against standard curves generated using known 
concentrations of pure hydroxyproline. 
 
Soluble collagen assay 
Soluble collagen was determined using Sircol Collagen Assay kits (Biocolor, 
Carrickfergus, BT, UK) according to the manufacturer’s instructions as 
described previously [22]. 
 
Mucus secreting cells 
Sections of mouse lung sections were deparaffinised and stained with 
Periodic acid-Schiff (PAS) using a commercially available kit (395B-1KT, 
Sigma-Aldrich) according to the manufacturer’s instructions; sections were 
immersed in periodic acid solution for 5 min at room temperature and 
following three rinses with distilled water incubated with Schiff's reagent for 15 
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min at room temperature, then counterstained with haematoxylin for 90 s. 
Mucus and goblet cells stain purple/magenta, whereas nuclear material stains 
blue. The number of PAS-positive cells per 100 μm length of airways was 




Longitudinal sections of mouse lungs were incubated with citrate buffer 
(10mM, pH6, 100 C, 35 min) for antigen retrieval. Non-specific binding was 
blocked with casein (5%, B6429,  Sigma-Aldrich, USA) at room temperature 
for 1 h. Slides were incubated with antibodies raised against Fbln1 (1:4,000, 
Abcam), Fn (1:2,000, Sigma-Aldrich, USA), Postn (1:2,000, Abcam) or Tnc 
(1:4,000, Santa Cruz Biotechnology) at 4 °C overnight, followed by anti-rabbit 
horseradish peroxidase-conjugated secondary antibody (HAF008, R&D 
Systems, Minneapolis, MN, USA) at 37 °C for 30 min. Diaminobenzidine 
(DAB, DAKO, Australia) was used as the chromogen and haematoxylin as a 
nuclear counterstain.  
 
Immunofluorescence 
Longitudinal sections of mouse lungs were deparaffinised and incubated with 
citrate buffer (10mM, pH6, 100 C, 35 min) for antigen retrieval. Non-specific 
binding was blocked with casein (5%, B6429, Sigma-Aldrich, USA) at room 
temperature for 1 h. Slides were incubated with anti-MUC5AC (1:100, 
ab3649, Abcam), or anti-MUC5B (1:200, sc-21768, Santa Cruz 
Biotechnology) antibodies at 4 °C overnight, followed by Cy3-conjugated anti-
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rabbit secondary antibody (R&D Systems) as described previously [60]. Some 
slides were incubated with an α-SMA antibody conjugated with Cy3 (c6198, 
Sigma-Aldrich) at 4°C overnight. Hoechst 33258 (1:200, 94403, Sigma-
Aldrich) was used to stain nuclei in the sections. The area of proteins was 




Isolated mouse lungs were inflated with 2% agarose gel dissolved in Hank's 
balanced salt solution, sectioned at 150 μm using a vibratome (VT 1000S, 
Leica), and incubated overnight in DMEM supplemented with 1% penicillin-
streptomycin. Lung slices were mounted in a custom-built perfusion chamber 
and perfused with increasing concentrations of methacholine. Dilator 
responses were assessed in airways pre-contracted with methacholine as 
described previously [35,36]. 
 
Bronchoalveolar lavage fluid (BALF) 
BALF was collected as described previously [22]. In brief, the multi-lobed lung 
was tied off and BALF was collected from the single-lobed lung by washing 
twice with PBS (500 μl). Cells were pelleted (150xg, 10 min) and resuspended 
in red blood cell lysis buffer. Remaining cells were cytocentrifuged (300 x g, 5 
min, ThermoFisher Scientific, Australia) onto microscope slides. Cells were 
stained with May-Grünwald-Giemsa and enumerated according to 




Concentrations of IL-5, IL-13, IL-33, TNF and CXCL1 proteins in lung tissue 
homogenates were determined using duoset ELISA kits (R&D Systems, 
Gymea, Australia) according to the manufacturer’s instructions and as 
described previously [27,37]. 
 
Lymph node and lung assays 
Cells from mouse lungs and draining lymph nodes were collected and filtered 
as described previously [39]. The cells were cultured with or without 5 μg/ml 
HDM for five days, and the levels of secreted IL-5 and IL-13 were measured 
by ELISA [27,38]. Some cells were stained with Th2 cell markers and 
enumerated by flow cytometry.  
 
Flow cytometry  
Single cell suspensions were prepared from mouse lungs and lymph nodes as 
described previously [31]. Cells were incubated with Fc-blocking buffer in the 
dark at room temperature for 30 min to prevent non-specific binding, then 
stained with CD4 conjugated to PE (60029, Stemcell Technologies, 
Vancouver, BC, Canada), CD3 conjugated to APC (100312., Biolegend, San 
Diego, CA, USA), and CD45 conjugated to PerCpCy5.5 (109828., Biolegend) 
antibodies according to the manufacturer’s instructions. Cells were then 
permeabilised and stained intracellularly with anti-GATA3 conjugated to 
PEcy7 (560405, BD Biosciences, Franklin Lakes, NJ, USA). Flow cytometric 
analysis was performed using a BD LSRFortessa X-20 Cytometer with 
 7 
FACSDiva software (BD Biosciences). Data was analysed using FlowJo 
software (Tree Star, Inc., Ashland, Oregon, USA) as described [40]. 
 
Dendritic cell (DC) and T cell cytokine release 
Mice in chronic HDM-induced experimental asthma and control groups were 
treated with Fbln1c-targeted siRNA or scrambled siRNA or vehicle. DCs and 
T cells were isolated from lung draining lymph nodes using EasySep kits 
(Stemcell Technologies, USA) according to the manufacturer’s instructions.  
DCs and T cells were co-cultured in DMEM medium with or without 5 μg/ml 
HDM for 5 days, and the levels of secreted IL-5 and IL-13 were measured by 
ELISA [39, 40]. 
 
In vitro experiments 
Cells of the human airway epithelial A549 line and epithelium derived from 
basal (BCi-NS1.1) cells [41] were cultured in Dulbecco's modified Eagle’s 
medium (DMEM, D5671, Sigma-Aldrich, USA) containing 5% fetal bovine 
serum (FBS, Bovogen, East Keilor, VIC, Australia), 25 mM 
hydroxyethylpiperazine-N'-2-ethanesulphonic acid buffer, 100 U/ml penicillin, 
and 100 μg/ml streptomycin at 37 °C in a 5% CO2 incubator. Fbln1c peptide 
(RCERLPCHENRECSKLPLRI) was obtained as described previously [43], 
and scrambled peptide (CCLECRRHRESNKPIRLLEP) was obtained from GL 
Biochem (Shanghai, China). Six-well plates were coated with human Fbln1c 
peptide (100 μg/ml) at room temperature, overnight. After three PBS washes, 
A549 or BCi-NS1.1 cells were seeded into wells with DMEM containing 0.1% 
FBS. Cells were lysed and RNA was extracted after 24 and 48 h. Total RNA 
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was reversed transcribed as described previously [41] and mRNA abundance 
determined by real-time quantitative PCR (qPCR) using human CXCL1 
primers (F:GCCAGTGCTTGCAGACCCT; R:GGCTATGACTTCGGTTTGGG), 
and expressed relative to the level of GAPDH mRNA (F: 
GTCGCTGTTGAAGTCAGAGG; R: GAAACTGTGGCGTGATGG). 
 
Statistics 
For mouse studies, results are presented as mean ± standard error of the 
mean (SEM) from 4–8 mice, in duplicate or triplicate experiments. Cell culture 
experiments were repeated at least three times for each time point. The 
statistical significance of differences between two group means was 
determined using two-tailed Student’s t-tests. Comparisons involving more 
than two groups used one-way or two-way analysis of variance (ANOVA) and 
Bonferroni post-test correction. GraphPad-Prism Software (version 6, 
GraphPad, La Jolla, CA, USA) was used to plot the data. 
